Obviously, from that headline I’m referring to GLP-1s and their many similar glucagon-like peptide-1 receptor agonist cohorts that have become a medical, healthcare, and even cultural zeitgeist over the course of the last couple of years. In fact, I bet every single person reading these words can sing the Ozempic jingle right now!
This month’s issue features a wealth of information on the studies that are spilling out of every peer-reviewed journal you can think of. Truly, an embarrassment of riches, and yet we barely scratched the surface with what we discuss on the following pages as more and more studies are released every day.
So, while no means an exhaustive list – and if you check this month’s Endocrine Society journals, you’ll see even more recently released research! – but it’s what we had to work with at the time of planning this issue.
Endocrine News published a clinical update in Research Highlights on 25 Feb 2026.
The item focuses on Miracle Drugs or Too Good to Be True?.
Review the original article for the full source wording and details.